Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cancer specific mortality in insulin-treated type 2 diabetes patients.

Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M.

PLoS One. 2014 Mar 25;9(3):e93132. doi: 10.1371/journal.pone.0093132. eCollection 2014.

2.

Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine.

Ioacara S, Guja C, Reghina A, Martin S, Sirbu A, Fica S.

J Diabetes Res. 2015;2015:962346. doi: 10.1155/2015/962346. Epub 2015 Jun 14.

3.

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.

Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N.

Diabetologia. 2012 Mar;55(3):644-53. doi: 10.1007/s00125-011-2429-5. Epub 2012 Jan 6.

4.

Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.

Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, Ferrara A.

Diabetes Care. 2013 Dec;36(12):3953-60. doi: 10.2337/dc13-0140. Epub 2013 Oct 29.

5.

Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.

Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS.

PLoS One. 2011;6(6):e21368. doi: 10.1371/journal.pone.0021368. Epub 2011 Jun 27.

6.

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.

Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH.

Diabetologia. 2012 Jan;55(1):51-62. doi: 10.1007/s00125-011-2312-4. Epub 2011 Sep 29.

7.

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT.

Diabetologia. 2009 Sep;52(9):1732-44. doi: 10.1007/s00125-009-1418-4. Epub 2009 Jun 30.

8.

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Colhoun HM; SDRN Epidemiology Group.

Diabetologia. 2009 Sep;52(9):1755-65. doi: 10.1007/s00125-009-1453-1. Epub 2009 Jul 15. Erratum in: Diabetologia. 2009 Nov;52(11):2469.

9.
10.

Long-term effects of insulin glargine on the risk of breast cancer.

Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M.

Diabetologia. 2011 Sep;54(9):2254-62. doi: 10.1007/s00125-011-2190-9. Epub 2011 May 26.

PMID:
21614572
11.

Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.

Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P.

Cardiovasc Diabetol. 2009 Feb 16;8:9. doi: 10.1186/1475-2840-8-9.

12.

Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.

Stürmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, Macdonald E, Wang R, Lavange LM, Pate V, Buse JB.

Diabetes Care. 2013 Nov;36(11):3517-25. doi: 10.2337/dc13-0263. Epub 2013 Jul 22.

13.

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.

Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O.

Curr Med Res Opin. 2012 Mar;28(3):439-46. doi: 10.1185/03007995.2012.654850. Epub 2012 Jan 23.

PMID:
22216894
14.

Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.

Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ.

Diabetes Obes Metab. 2015 Apr;17(4):350-62. doi: 10.1111/dom.12412. Epub 2014 Dec 10.

PMID:
25399739
15.
16.

Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy.

Cammarota S, Bruzzese D, Catapano AL, Citarella A, De Luca L, Manzoli L, Masulli M, Menditto E, Mezzetti A, Riegler S, Putignano D, Tragni E, Novellino E, Riccardi G.

Nutr Metab Cardiovasc Dis. 2014 Jan;24(1):10-7. doi: 10.1016/j.numecd.2013.04.002. Epub 2013 Jun 24.

PMID:
23806740
18.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

19.

Insulin glargine use and breast cancer risk: Associations with cumulative exposure.

Peeters PJ, Bazelier MT, Leufkens HG, Auvinen A, van Staa TP, de Vries F, De Bruin ML.

Acta Oncol. 2016 Jul;55(7):851-8. doi: 10.3109/0284186X.2016.1155736. Epub 2016 May 6.

20.

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.

Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM.

Diabetes Care. 2010 Sep;33(9):1997-2003. doi: 10.2337/dc10-0476. Epub 2010 Jun 14.

Supplemental Content

Support Center